The Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire: Development of a Conceptual Model and Disease-Specific Patient-Reported Outcome Measure

References

• Cleveland Clinic. Amyloidosis: ATTR; 2019. Available from: https://my.clevelandclinic.org/health/diseases/17855-amyloidosis-attr. Accessed October 04, 2019.
   Google Scholar
• Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86(9):1036–1043. doi:10.1136/jnnp-2014-308724
   PubMed Web of Science ®Google Scholar
• Adams D, Koike H, Slama M, et al. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol. 2019;15(7):387–404. doi:10.1038/s41582-019-0210-4
   PubMed Web of Science ®Google Scholar
• Coelho T, Ericzon FR, et al. A guide to transthyretin amyloidosis; 2016.
   Google Scholar
• Obi CA, Mostertz WC, Griffin JM, et al. ATTR epidemiology, genetics, and prognostic factors. Methodist DeBakey Cardiovasc J. 2022;18:17–26. doi:10.14797/mdcvj.1066
   PubMedGoogle Scholar
• Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68(2):161–172. doi:10.1016/j.jacc.2016.03.596
   PubMed Web of Science ®Google Scholar
• Shije JZ, Bautista MAB, Smotherman C. The frequency of V122I transthyretin mutation in a cohort of African American individuals with bilateral carpal tunnel syndrome. Front Neurol. 2022;13:949401. doi:10.3389/fneur.2022.949401
   PubMed Web of Science ®Google Scholar
• Minnella AM, Rissotto R, Antoniazzi E, et al. Ocular involvement in hereditary amyloidosis. Genes. 2021:12. doi:10.3390/genes12070955
   PubMed Web of Science ®Google Scholar
• Sousa L, Coelho T, Taipa R. CNS involvement in hereditary transthyretin amyloidosis. Neurology. 2021;97(24):1111–1119. doi:10.1212/WNL.0000000000012965
   PubMed Web of Science ®Google Scholar
• Taipa R, Sousa L, Pinto M, et al. Neuropathology of central nervous system involvement in TTR amyloidosis. Acta Neuropathol. 2023;145(1):113–126. doi:10.1007/s00401-022-02501-9
   PubMed Web of Science ®Google Scholar
• Adams D, Suhr OB, Dyck PJ, et al. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol. 2017;17(1):181. doi:10.1186/s12883-017-0948-5
   PubMed Web of Science ®Google Scholar
• Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66(21):2451–2466. doi:10.1016/j.jacc.2015.09.075
   PubMed Web of Science ®Google Scholar
• González-López E, Gagliardi C, Dominguez F, et al. Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J. 2017;38(24):1895–1904. doi:10.1093/eurheartj/ehx043
   PubMed Web of Science ®Google Scholar
• Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23:S107–S112.
   PubMed Web of Science ®Google Scholar
• Wixner J, Mundayat R, Karayal ON, et al. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis. 2014;9(1):61. doi:10.1186/1750-1172-9-61
   PubMedGoogle Scholar
• Coelho T, Maurer MS, Suhr OB. THAOS - the transthyretin amyloidosis outcomes survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63–76. doi:10.1185/03007995.2012.754348
   PubMed Web of Science ®Google Scholar
• Denoncourt RN, Adams D, Gonzalez-Duarte A, et al. Burden of illness for patients with hereditary attr amyloidosis with polyneuropathy begins with symptom onset and increases with disease progression. Value Health. 2016;19(7):A436. doi:10.1016/j.jval.2016.09.518
   Web of Science ®Google Scholar
• Grogan M, Dispenzieri A, Carlsson M, et al. Description of the health-related quality of life of transthyretin amyloid cardiomyopathy subjects from the transthyretin amyloidosis outcomes survey. J Card Fail. 2017;23(8):S102. doi:10.1016/j.cardfail.2017.07.298
   Web of Science ®Google Scholar
• Stewart M, Loftus J, Lenderking WR, et al. Characterizing disease burden in an ultra-rare disease in the United States: transthyretin (TTR) amyloidosis patients and caregivers. Value Health. 2013;16(7):A386. doi:10.1016/j.jval.2013.08.365
   Web of Science ®Google Scholar
• Amyloidosis research consortium advancing amyloidosis: a research roadmap. Available from: https://www.arci.org/wp-content/uploads/2019/03/ARC-White-Paper-Final-v3.pdf. Accessed September 06, 2019.
   Google Scholar
• Aimo A, Rapezzi C, Perfetto F, et al. Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. Eur J Clin Invest. 2021;51(11):e13598. doi:10.1111/eci.13598
   PubMed Web of Science ®Google Scholar
• Rizio AA, Broderick LE, White MK, et al. Content validation of the ATTR amyloidosis patient symptom survey: findings from patient and clinician cognitive debriefing interviews. Patient Relat Outcome Meas. 2020;11:149–160. doi:10.2147/PROM.S264034
   PubMed Web of Science ®Google Scholar
• Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2–assessing respondent understanding. Value Health. 2011;14:978–988. doi:10.1016/j.jval.2011.06.013
   PubMed Web of Science ®Google Scholar
• Terwee CB, Prinsen CA, Chiarotto A, et al. COSMIN methodology for assessing the content validity of PROMs: user manual, version 1.0; 2018.
   Google Scholar
• Crossnohere NL, Brundage M, Calvert MJ, et al. International guidance on the selection of patient-reported outcome measures in clinical trials: a review. Qual Life Res. 2021;30(1):21–40. doi:10.1007/s11136-020-02625-z
   PubMed Web of Science ®Google Scholar
• Willis G. Cognitive Interviewing. Thousand Oaks, California: SAGE Publications; 2005.
   Google Scholar
• US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input: guidance for industry, food and drug administration staff, and other stakeholders; 2020. Available from: https://www.fda.gov/media/139088/download. Accessed July 12, 2021.
   Google Scholar
• Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health. 2011;14:967–977. doi:10.1016/j.jval.2011.06.014
   PubMed Web of Science ®Google Scholar
• Cheng KKF, Clark AM. Qualitative methods and patient-reported outcomes. Int J Qual Methods. 2017;16(1):160940691770298. doi:10.1177/1609406917702983
   Google Scholar
• US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims; 2009. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf.%20Updated%20March%2023,%202017. Accessed March 25, 2019.
   Google Scholar
• US Food and Drug Administration. Patient-focused drug development guidance public workshop: methods to identify what is important to patients and select, develop or modify fit-for-purpose clinical outcomes assessments; 2018. Available from: https://www.fda.gov/downloads/Drugs/NewsEvents/UCM620708.pdf. Accessed March 25, 2019.
   Google Scholar
• Damy T, Conceição I, García-Pavía P, et al. A simple core dataset and disease severity score for hereditary transthyretin (ATTRv) amyloidosis. Amyloid. 2021:1–10. doi:10.1080/13506129.2021.1931099
   Google Scholar
• Wajnsztajn Yungher F, Kim A, Boehme A, et al. Peripheral neuropathy symptoms in wild type transthyretin amyloidosis. J Peripher Nerv Syst. 2020;25:265–272. doi:10.1111/jns.12403
   PubMed Web of Science ®Google Scholar
• Sabbour H, Hasan KY, Al Badarin F, et al. From clinical clues to final diagnosis: the return of detective work to clinical medicine in cardiac amyloidosis. Front Cardiovasc Med. 2021;8:644508. doi:10.3389/fcvm.2021.644508
   PubMed Web of Science ®Google Scholar
• O’Connor M, Broderick L, Brown D, et al. Comparison of symptoms experienced by patients with ATTRwt and hATTR: findings from the development of an ATTR-specific PRO. Presentation at Presented at the 2021 3rd European ATTR Amyloidosis Meeting for Patients and Doctors, September 6–8; 2021.
   Google Scholar